Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
The purpose of this study is to evaluate desmoteplase (which is a manufactured protein
 derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of
 blood through one (or more) of the blood vessels supplying the brain, thereby reopening the
 blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic
 stroke.
Inclusion Criteria:

 -  Eligible for study treatment within 3-9 hours after onset of stroke symptoms.

 -  Score of 4-24 on the NIHSS with clinical signs of hemispheric infarction (i.e.
 hemiparesis) suggestive of ischemic stroke.

 Inclusion Criteria from diagnostic imaging screening:

 -  Distinct penumbra (at least 20%), measured by MRI (PWI/DWI) or perfusion CT, related
 to middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral
 artery (PCA) territory in a hemispheric distribution.

 Exclusion Criteria:

 -  History or clinical presentation of intracranial hemorrhage (ICH), subarachnoid
 hemorrhage, arteriovenous malformation, aneurysm, or cerebral neoplasm.

 -  Rapidly improving neurological symptoms.

 -  Pre-stroke MRS score of > 1 (including previous disability).

 -  Suspected acute vertebral or basilar artery occlusion.

 -  Current use of anticoagulants and a prolonged prothrombin time.

 -  Uncontrolled hypertension.

 -  Baseline hematocrit of < 0.25.

 -  Baseline platelet count < 100,000/mm3.